---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-092099"
form_type: "8-K"
ticker: "CLDX"
cik: "0000744218"
company_name: "Celldex Therapeutics, Inc."
filed_at: "2021-07-14T23:59:59+00:00"
generated_at: "2026-06-30T05:33:10.634317+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Celldex prices upsized $250M public offering at $42/share; net proceeds ~$234.8M

## Summary
- Celldex priced 5,952,381 shares at $42.00 per share in an upsized public offering for $250M gross proceeds.
- Expected net proceeds of ~$234.8M after underwriting discounts and estimated expenses.
- Proceeds to fund clinical development of CDX-0159 and other pipeline candidates, and bispecific antibody platform.
- Underwriters have 30-day option to purchase up to 892,857 additional shares at the same price.
- Offering expected to close July 16, 2021; joint book-runners: Jefferies, SVB Leerink, Guggenheim, Cantor.

## SEC filing metadata
- accession: 0001104659-21-092099
- form_type: 8-K
- ticker: CLDX
- cik: 0000744218
- company_name: Celldex Therapeutics, Inc.
- filed_at: 2021-07-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744218/000110465921092099/0001104659-21-092099-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744218/000110465921092099/tm2121701d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-092099
- JSON: https://secwatch.observer/filing/0001104659-21-092099.json
- Plain text: https://secwatch.observer/filing/0001104659-21-092099.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.